PMID- 37366301
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230902
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 15
DP  - 2023 Aug
TI  - Clinical characteristics, tumor-infiltrating lymphocytes, and prognosis in 
      HER2-low breast cancer: A comparison study with HER2-zero and HER2-positive 
      disease.
PG  - 16264-16278
LID - 10.1002/cam4.6290 [doi]
AB  - INTRODUCTION: HER2-low breast cancer is a gradually recognized and unexplored 
      group of diseases. We aimed to investigate the clinical and prognosis features 
      and to identify the role of stromal tumor-infiltrating lymphocytes (sTILs) in 
      this population. METHODS: Consecutive primary breast cancer patients treated 
      between January 2009 to June 2013 were retrospectively reviewed. HER2-low was 
      defined as immunohistochemistry (IHC) 1+, or 2+ and fluorescence in situ 
      hybridization (FISH) negative. sTILs were scored following the international 
      guidelines. Clinicopathologic features and survival were compared according to 
      HER2 and sTILs category. RESULTS: A total of 973 breast cancer patients were 
      enrolled, including 615 (63.2%) HER2-low patients. HER2-low patients shared more 
      similarity with HER2-0 cases in clinicopathological features. sTILs in HER2-Low 
      patients was comparable to HER2-0 patients (p = 0.064), both significantly lower 
      than HER2-positive ones (p < 0.001). Meanwhile, tumors with sTILs >/=50% accounted 
      for the least proportion of HER2-low cases (p < 0.001). HER2 status had no 
      significant influence on recurrence-free survival (RFS, p = 0.901) in the whole 
      population. However, in the estrogen receptor (ER)-negative subgroup, HER2-low 
      was related to worse RFS (p = 0.009) and OS (p = 0.001) compared with 
      HER2-positive ones. sTILs increment was an independent favorable prognostic 
      factor in the whole (OS, p = 0.003; RFS, p = 0.005) and HER2-low population (OS, 
      p = 0.007; RFS, p = 0.009) after adjusted to clinicopathological parameters. 
      CONCLUSIONS: HER2-low patients shared similar clinicopathological features with 
      HER2-0 rather than HER2-positive cases and had relatively low sTILs. 
      ER-negative/HER2-low patients had significantly inferior survival. sTILs 
      increment was independently associated with favorable survival in the HER2-low 
      group, suggesting a potential benefit from a novel treatment strategy.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Lu, Yujie
AU  - Lu Y
AUID- ORCID: 0000-0002-9630-2390
AD  - Department of General Surgery, Comprehensive Breast Health Center, Ruijin 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Tong, Yiwei
AU  - Tong Y
AD  - Department of General Surgery, Comprehensive Breast Health Center, Ruijin 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Fei, Xiaochun
AU  - Fei X
AD  - Department of Pathology, Comprehensive Breast Health Center, Ruijin Hospital, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Chen, Xiaosong
AU  - Chen X
AUID- ORCID: 0000-0002-0036-9444
AD  - Department of General Surgery, Comprehensive Breast Health Center, Ruijin 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Shen, Kunwei
AU  - Shen K
AD  - Department of General Surgery, Comprehensive Breast Health Center, Ruijin 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230627
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Disease-Free Survival
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphocytes, Tumor-Infiltrating
MH  - Prognosis
MH  - Receptor, ErbB-2
MH  - Retrospective Studies
MH  - *Breast Neoplasms/diagnosis
PMC - PMC10469737
OTO - NOTNLM
OT  - HER2-low
OT  - breast cancer
OT  - sTILs
OT  - survival
COIS- The authors declare no competing interests.
EDAT- 2023/06/27 13:11
MHDA- 2023/09/01 06:43
PMCR- 2023/06/27
CRDT- 2023/06/27 07:12
PHST- 2023/05/15 00:00 [revised]
PHST- 2022/10/14 00:00 [received]
PHST- 2023/06/15 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/06/27 13:11 [pubmed]
PHST- 2023/06/27 07:12 [entrez]
PHST- 2023/06/27 00:00 [pmc-release]
AID - CAM46290 [pii]
AID - 10.1002/cam4.6290 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Aug;12(15):16264-16278. doi: 10.1002/cam4.6290. Epub 2023 Jun 
      27.